Science 37 Accelerates Asthma Trial Enrollment by 22x

Clinical trials are a crucial part of medical research, and Science 37 is revolutionizing the way these studies are conducted. By leveraging technology, Science 37 enables patients to participate in clinical trials from the comfort of their homes, making the process more accessible and convenient.

The company offers a range of active and enrolling clinical trials, covering a variety of medical conditions. For instance, there is a study focused on C. difficile infection, where participants can contribute to shaping the future of research on this condition. Another study is aimed at Type 2 Diabetes in Denmark, where participants can help advance understanding of the disease through digital monitoring of blood sugar and activity levels.

Science 37 also supports research on Fragile X Syndrome, a genetic condition that causes developmental problems and learning disabilities. The VEDS study is evaluating the effects of celiprolol on vascular Ehlers-Danlos Syndrome, a rare connective tissue disorder. Additionally, there is a head and neck cancer research study for individuals diagnosed with specific types of cancer, as well as a clinical study for classical homocystinuria, a rare metabolic disorder.

Upcoming studies include research on rhinosinusitis, a common condition characterized by a runny and stuffy nose, facial pain, and loss of smell. There are also trials for Type 2 Diabetes, rare diseases, and various other conditions affecting the digestive system, dermatology, cardiovascular health, neurology, immune system, respiratory health, and cancer.

Science 37's approach to clinical trials is distinct due to its decentralized nature, allowing for a more diverse and inclusive participant pool. The process is designed to be straightforward, with participants able to receive study supplies at home, and there is no cost to participate. The duration of a study varies, but Science 37 ensures that the process is clear and well-managed.

Volunteering for a clinical trial can be a significant decision, and Science 37 provides resources to help individuals understand the implications and benefits. Participants can discuss their involvement with their healthcare providers, and the company emphasizes the importance of maintaining open communication throughout the trial.

Science 37's innovative approach to clinical trials aims to accelerate medical research by making it more accessible to a broader range of patients. By combining technology with traditional research methods, the company is helping to uncover new treatments and improve patient care across a spectrum of medical conditions.